KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) EBIAT (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBIAT for 15 consecutive years, with -$4.1 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 126.78% to -$4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$38.6 million through Dec 2025, down 152.19% year-over-year, with the annual reading at -$38.6 million for FY2025, 152.19% down from the prior year.
  • EBIAT for Q4 2025 was -$4.1 million at Supernus Pharmaceuticals, up from -$45.1 million in the prior quarter.
  • The five-year high for EBIAT was $38.5 million in Q3 2024, with the low at -$45.1 million in Q3 2025.
  • Average EBIAT over 5 years is $7.5 million, with a median of $6.8 million recorded in 2021.
  • The sharpest move saw EBIAT soared 2496.63% in 2024, then crashed 9637.9% in 2025.
  • Over 5 years, EBIAT stood at $2.4 million in 2021, then soared by 943.45% to $25.5 million in 2022, then plummeted by 95.39% to $1.2 million in 2023, then surged by 1204.51% to $15.3 million in 2024, then plummeted by 126.78% to -$4.1 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$4.1 million, -$45.1 million, and $22.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.